Lung cancer is one of the most common cancers in the United States and Europe and the leading cause of cancer death for both men and women in the United States, with approximately 160,000 patient deaths per year. Nonsmall cell lung cancer (NSCLC) comprises 85% of lung cancer cases of which up to 40% have adenocarcinoma histology. Patients diagnosed with stage I and II adenocarcinoma (localized disease) have 5-year overall mortality rates ranging from 30% in stage IA, 50% in stage IB disease, and up to 66% in stage II.
1 x 1 Tsuboi, M, Ohira, T, Saji, H et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2007; 13: 73–77 PubMed | Google Scholar See all References ,
2 x 2 Chansky, K, Sculier, JP, Crowley, JJ, Giroux, D, Van Meerbeeck, J, and Goldstraw, P. International Staging Committee and Participating Institutions. . The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009; 4: 792–801 Abstract | Full Text | Full Text PDF | PubMed | Scopus (267) | Google Scholar See all References